These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
356 related items for PubMed ID: 16682287
1. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma. Spitz R, Betts DR, Simon T, Boensch M, Oestreich J, Niggli FK, Ernestus K, Berthold F, Hero B. Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287 [Abstract] [Full Text] [Related]
3. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Spitz R, Hero B, Simon T, Berthold F. Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3368-73. PubMed ID: 16740759 [Abstract] [Full Text] [Related]
4. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Spitz R, Hero B, Ernestus K, Berthold F. Clin Cancer Res; 2003 Oct 15; 9(13):4835-40. PubMed ID: 14581355 [Abstract] [Full Text] [Related]
6. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT. J Clin Oncol; 2005 Sep 20; 23(27):6466-73. PubMed ID: 16116152 [Abstract] [Full Text] [Related]
13. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F. Eur J Cancer; 2004 Dec 20; 40(18):2753-9. PubMed ID: 15571958 [Abstract] [Full Text] [Related]
14. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. J Clin Oncol; 2005 Sep 20; 23(27):6474-80. PubMed ID: 16116154 [Abstract] [Full Text] [Related]
15. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F. Genes Chromosomes Cancer; 2006 Dec 20; 45(12):1130-42. PubMed ID: 16958102 [Abstract] [Full Text] [Related]
18. [The neuroblastoma, "enfant terrible" among pediatric tumors]. Laureys G. Verh K Acad Geneeskd Belg; 2003 Dec 20; 65(1):5-23; discussion 23-8. PubMed ID: 12802894 [Abstract] [Full Text] [Related]
19. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. J Clin Oncol; 2005 Sep 20; 23(27):6459-65. PubMed ID: 16116153 [Abstract] [Full Text] [Related]
20. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F. J Clin Oncol; 2005 Apr 01; 23(10):2280-99. PubMed ID: 15800319 [Abstract] [Full Text] [Related] Page: [Next] [New Search]